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Thirty laboratory dogs were randomly assigned to two groups (A and B) of 15 dogs and 23 subcutaneously vaccinated with a single dose of one of two commercially available 24 monovalent inactivated rabies vaccines: RABISIN ® (Merial, France)(group A) and 25 NOBIVAC ® Rabies (Intervet International)(group B). Rabies antibodies were measured over 26 a period of 4 months using the fluorescent antibody virus neutralization (FAVN) test. The two 27 vaccines performed differently in terms of magnitude and persistence of rabies antibodies 28 titers in dogs. Two weeks after vaccination, average rabies antibody titers peaked at 2.53 29 IU/mL (range, 0.17 -13.77 IU/mL) and 1.26 IU/mL (range, 0.50 -4.56 IU/mL) in group A 30 and B dogs, respectively. The average FAVN antibody titres against rabies on D28, D56, D84, 31 D112 and D120 were significantly higher in group A than in group B. Although all dogs from 32 group B serologically responded to vaccination, the proportion of dogs with antibody titres 33 0.5 IU/mL dropped significantly after D28 and was statistically significantly lower on D56, 34 The rules for non-commercial movement of pet animals (dog, cat, ferret) are laid down in 46 directive 998/2003 of the European Community. It requires the identification of the animal by 47 tattoo and/or microchip, a certificate of vaccination against rabies, and a 21-day waiting 48 period in case of primary vaccination. In addition, in four countries (United-Kingdom [UK], 49
Ireland, Sweden and Malta), for a transitional period of 5 years, animals have to be tested for 50 rabies antibodies within the period specified in their national rules (30 days after vaccination 51 are recommended for UK, Ireland and Malta, and at least 4 months for Sweden). The Pet 52
Travel Scheme (PETS) procedure, applied in the UK and Ireland, also requires that the pet 53 must wait for 6 months after blood sampling before entering those countries. When importing 54 animals from rabies-infected third countries into the E.U., pets must be tested for rabies 55 antibodies 30 days after vaccination and wait for 3 additional months after blood sampling 56 before entering into the E.U. The blood testing has two main objectives. One is to check that 57 the animal has developed an adequate humoral immune response to vaccination (efficacy); the 58 other is to ensure that it has been properly vaccinated (compliance). 59
Recently, the European Food Safety Authority (EFSA) was asked to assess the risk of rabies 60 introduction into the UK, Ireland, Sweden, or Malta, as a consequence of abandoning the 61 serological test for rabies. EFSA opinion was published in February 2006 (EFSA, 2006) . 62
Based on the known efficacy of authorised rabies vaccines, EFSA recommended testing for 63 rabies antibodies (or carrying out a second rabies vaccination) only those animals coming 64 from European countries with a no negligible risk of rabies i.e. an annual incidence in the 65 domestic pet population higher than one infected animal per million. 66 M a n u s c r i p t 4 To obtain marketing authorisation in European countries, rabies vaccines for veterinary use 68 have to fulfil a number of tests in terms of immunogenicity, potency and safety (European 69
Pharmacopoeia 2007). 70
In this study, the kinetics of neutralizing rabies antibodies were compared in dogs over a 71 period of 4 months after the administration of two commercially available inactivated 72
adjuvanted monovalent rabies vaccines, tested under the same experimental conditions. 73
74
The following commercially available monovalent inactivated rabies vaccines were used. 75 RABISIN  (Merial SAS, France, batch No.L185053) containing the G52 fixed virus of the 76 Pasteur strain at 1IU/dose and NOBIVAC  Rabies (Intervet Nederland B.V., batch 77
No.74120D) containing the Pasteur RIV strain at 2 IU/dose. The two strains have different 78 passage histories and were inactivated for vaccine production. Both vaccines were 79 administered according to the recommendations of the Manufacturer's, i.e. one dose from the 80 age of 3 months. From here on, RABISIN and NOBIVAC Rabies will be referred to as 81 vaccine A and B, respectively. 82 Thirty (30) conventional Beagles, 13 to 18 weeks old, were obtained from an accredited 83 commercial supplier and randomly assigned to two groups (A and B) of 15 animals each 84 according to sex, age and weight. Dogs were conventionally housed and fed a high quality 85 commercial dry ration with unlimited access to water. Dogs were identified by a microchip 86 implanted subcutaneously. On D0, dogs from group A and B were vaccinated with a single 87 dose of vaccine A and B, respectively. All vaccines were administered subcutaneously 88 between the shoulder blades. 89
Blood samples were collected from all puppies at regular intervals following vaccination (D0, 90 Furthermore, the number of dogs with a titer of at least 0.50 IU/ml was compared between 99 groups by fitting a logistic regression model with factors "group" and "day" and the 100 corresponding interaction. For both parameters, due to a group x day interaction, comparison 101 between groups was performed day-by-day for the D14-D120 period by a Fisher's F-test with 102 adjusted 1 st error risk (Bonferroni's method). 103 104 All, but two puppies were seronegative for rabies at the start of the study (Table 1) . Two 105 puppies from group A (Nos.2 and 9) had a SN titer of 0.66 IU/mL, which most probably 106 represented residual maternal antibodies. Two weeks after vaccination, average rabies 107 antibody titers peaked at 2.53 IU/mL (range, 0.17 -13.77 IU/mL) and 1.26 IU/mL (range 108 0.50 -4.56 IU/mL) in group A and B dogs, respectively (Table 1) . A significant "group x 109 day" (p = 0.0004) and "group" effect (p < 0.0001) was found for the period D14-D120, 110
indicating that the kinetics of antibody responses to vaccination differed between the two 111 groups of dogs. Time-by-time comparison showed that the average FAVN antibody titers 112 against rabies on D28, D56, D84, D112 and D120 were significantly higher in the dogs from 113 group A when compared to the titers in group B (Figure 1 ). One dog (No.10) from group A 114 did not reach 0.5 IU/mL and two dogs from group B (Nos.19 and 23) developed maximum 115 SN titers just above the WHO threshold value (Table 1) laboratory dogs are known to respond better to vaccination than pet dogs (Aubert, 1992 ). An 133 in-depth review of many experimental studies (Aubert, 1993) has shown a strong correlation 134 between the development of rabies antibodies after vaccination and protection against rabies 135 infection. This correlation is independent of the interval between vaccination and blood 136 sampling (Aubert, 1992) . The OIE and WHO (1992) have defined the protective threshold at 137 0.50 IU/mL in humans in absence of challenge data, and this threshold has been extended to 138 animals. Several studies on the sensitivity of the FAVN test have shown that a threshold of 139 positivity of 0.24 IU/ml could be adopted (Cliquet et al. 1998 test failure significantly increased when dogs were tested beyond 6 weeks after vaccination. 169
In contrast, for multiple vaccinated dogs, antibody titers did not depend on the time elapsed 170 since the last vaccination (Cliquet et al. 2003) . As a consequence, the use of two doses of 171 vaccine for primo-vaccination is currently recommended to obtain high and sustained 172 antibody titers (Toma, 1994) . To the best of our knowledge there is no comparative published 173 data on the use of two doses of vaccine. It is now generally accepted that, in order to increase 174 the success of passing the serological test, monovalent rabies vaccines should be used 175 (Cliquet et al. 2003) . Several other factors such as age, reproductive status, and 176 immunosuppression play an important role as well (Aubert 1992 
